| Study in Children and Adolescents of 177Lu-DOTATATE (Lutathera®) Combined With the PARP Inhibitor Olaparib for the Treatment of Recurrent or Relapsed Solid Tumours Expressing Somatostatin Receptor (SSTR) (LuPARPed). NCT06607692 Fundación de investigación HM | Hasta alıyor | Faz 1, Faz 2 | 20 Eylül 2024 |
| Testing the Addition of Sunitinib Malate to Lutetium Lu 177 Dotatate (Lutathera) in Pancreatic Neuroendocrine Tumors NCT05687123 National Cancer Institute (NCI) | Hasta alıyor | Faz 1 | 14 Ağustos 2024 |
| NEPC Study: An Exploratory Safety and Efficacy Study With PSMA, SSTR2 and GRPR Targeted Radioligand Therapy in Metastatic Neuroendocrine Prostate Cancer. NCT06379217 Novartis Pharmaceuticals | Aktif, hasta almıyor | Faz 1 | 29 Temmuz 2024 |
| A Clinical Study of Lutetium[177Lu] Oxodotreotide Injection in Patients With Advanced Neuroendocrine Neoplasms NCT06398444 Sinotau Pharmaceutical Group | Hasta alıyor | Faz 2, Faz 3 | 11 Haziran 2024 |
| Surgical Debulking Prior to Peptide Receptor Radionuclide Therapy in Well Differentiated Gastroenteropancreatic Neuroendocrine Tumors NCT06016855 Vanderbilt-Ingram Cancer Center | Hasta alıyor | Faz 4 | 31 Mayıs 2024 |
| 177Lu-DOTATATE Modified Delivery Based on Individualized Dosimetry NCT06395402 University of Iowa | Hasta alıyor | Faz 2 | 3 Mayıs 2024 |
| Multi-modal Characterisation of Gastroenteropancreatic Neuroendocrine Tumours (GEP-NETs) Treated With Targeted Radionuclide Therapy (TRT): Prospective Interventional Multicentre National Cohort NCT06256705 Assistance Publique - Hôpitaux de Paris | Hasta alıyor | Uygulanmaz | 25 Mart 2024 |
| Comparing Retreatment of 177Lu-DOTATATE PRRT Versus the Usual Treatment in Patients With Metastatic Unresectable Gastroenteropancreatic Neuroendocrine Tumors, NET RETREAT Trial NCT05773274 National Cancer Institute (NCI) | Hasta alıyor | Faz 2 | 12 Ocak 2024 |
| Testing the Safety and Effectiveness of Radiation-based Treatment (Lutetium Lu 177 Dotatate) for Metastatic Prostate Cancer That Has Neuroendocrine Cells NCT05691465 National Cancer Institute (NCI) | Hasta alıyor | Faz 2 | 27 Aralık 2023 |
| Trial of Lu-177 DOTATATE (Lutathera®) in Unlicensed Indications NCT06121271 University College, London | Henüz hasta almıyor | Faz 2 | 18 Aralık 2023 |
| A Phase III Clinical Study to Compare the Safety and Efficacy of 177Lu-DOTATATE Injection and Long-acting Oxytrexine in Adult Patients With NETs NCT07057622 HTA Co., Ltd. | Hasta alıyor | Faz 3 | 12 Aralık 2023 |
| Testing the Effectiveness of an Anti-cancer Drug, Triapine, When Used With Targeted Radiation-based Treatment (Lutetium Lu 177 Dotatate), Compared to Lutetium Lu 177 Dotatate Alone for Metastatic Neuroendocrine Tumors NCT05724108 National Cancer Institute (NCI) | Aktif, hasta almıyor | Faz 2 | 30 Ağustos 2023 |
| Phase II Study of Peptide Receptor Radionuclide Therapy in Combination With Immunotherapy for Patients With Merkel Cell Cancer NCT05583708 Weill Medical College of Cornell University | Hasta alıyor | Faz 2 | 3 Ağustos 2023 |
| Comparing Capecitabine and Temozolomide in Combination to Lutetium Lu 177 Dotatate in Patients With Advanced Pancreatic Neuroendocrine Tumors, the ComPareNET Trial NCT05247905 Alliance for Clinical Trials in Oncology | Aktif, hasta almıyor | Faz 2 | 16 Şubat 2023 |
| Testing Lutetium Lu 177 Dotatate in Patients With Somatostatin Receptor Positive Advanced Bronchial Neuroendocrine Tumors NCT04665739 National Cancer Institute (NCI) | Hasta alıyor | Faz 2 | 3 Şubat 2023 |
| Study of Cabozantinib With Lu-177 in Patients With Somatostatin Receptor 2 Positive Neuroendocrine Tumors NCT05249114 Providence Health & Services | Aktif, hasta almıyor | Faz 1 | 28 Aralık 2022 |
| Lutathera for Treatment of Recurrent or Progressive High-Grade CNS Tumors NCT05278208 Nationwide Children's Hospital | Hasta alıyor | Faz 1, Faz 2 | 21 Kasım 2022 |
| Lu-177-DOTATATE (Lutathera) in Combination With Olaparib in Inoperable Gastroenteropancreatico Neuroendocrine Tumors (GEP-NET) NCT04086485 National Cancer Institute (NCI) | Hasta alıyor | Faz 1, Faz 2 | 3 Ekim 2022 |
| Study to Evaluate Safety and Dosimetry of Lutathera in Adolescent Patients With GEP-NETs and PPGLs NCT04711135 Advanced Accelerator Applications Sonuç yayımlandı | Aktif, hasta almıyor | Faz 2 | 31 Ağustos 2022 |
| A Study Comparing Treatment With Lutetium[177Lu] Oxodotreotide Injection to Octreotide LAR in Patients With GEP-NETs NCT05459844 Sinotau Pharmaceutical Group | Aktif, hasta almıyor | Faz 3 | 31 Ağustos 2022 |
| A Study of [177Lu]Lu-DOTA-TATE in Newly Diagnosed ES-SCLC Patients in Combination With Carboplatin, Etoposide and Atezolizumab NCT05142696 Novartis Pharmaceuticals | Aktif, hasta almıyor | Faz 1, Faz 2 | 13 Temmuz 2022 |
| Improving Peptide Receptor Radionuclide Therapy With PARP Inhibitors NCT05870423 Erasmus Medical Center | Hasta alıyor | Faz 1 | 1 Haziran 2022 |
| A Dose Finding Study of [177Lu]Lu-DOTA-TATE in Newly Diagnosed Glioblastoma in Combination With Standard of Care and in Recurrent Glioblastoma as a Single Agent. NCT05109728 Novartis Pharmaceuticals | Aktif, hasta almıyor | Faz 1 | 10 Mayıs 2022 |
| Lutathera and ASTX727 in Neuroendocrine Tumours NCT05178693 Imperial College London | Hasta alıyor | Faz 1 | 25 Nisan 2022 |
| PARP Inhibitor With 177Lu-DOTA-Octreotate PRRT in Patients With Neuroendocrine Tumours NCT05053854 Peter MacCallum Cancer Centre, Australia | Hasta alıyor | Faz 1 | 8 Aralık 2021 |
| Assessment of Retreatment With Lutathera® in Patients With New Progression of Intestinal Well-differenciated NET NCT04954820 Institut du Cancer de Montpellier - Val d'Aurelle | Hasta alıyor | Faz 2 | 18 Ekim 2021 |
| Intra-arterial Hepatic (IAH) Infusion of Radiolabelled Somatostatin Analogs in GEP-NET Patients With Dominant Liver Metastases NCT04837885 University Hospital, Bordeaux | Hasta alıyor | Faz 2 | 24 Eylül 2021 |
| Testing the Addition of An Anti-cancer Drug, M3814 (Peposertib), to the Usual Radiation-Based Treatment (Lutetium Lu 177 Dotatate) for Pancreatic Neuroendocrine Tumors NCT04750954 National Cancer Institute (NCI) | Aktif, hasta almıyor | Faz 1 | 22 Temmuz 2021 |
| 177Lutetium-DOTATATE in Children With Primary Refractory or Relapsed High-risk Neuroblastoma NCT04903899 Jakob Stenman | Hasta alıyor | Faz 2 | 19 Mayıs 2021 |
| Spanish Series of Patients Treated With the Radionuclide Lutetium177 NCT04949282 Sociedad Española de Medicina Nuclear e Imagen Molecular | Hasta alıyor | — | 10 Mayıs 2021 |
| Study of PRRT in Metastatic, WHO Grade 1 or 2, SSTR Positive, GEP-NET Who Are Candidates for Cytoreductive Surgery NCT04609592 Stanford University | Aktif, hasta almıyor | Faz 1 | 17 Mart 2021 |
| Targeted Therapy and Avelumab in Merkel Cell Carcinoma NCT04261855 Melanoma and Skin Cancer Trials Limited | Aktif, hasta almıyor | Faz 1, Faz 2 | 8 Ekim 2020 |
| Lutathera in People With Gastroenteropancreatic (GEP), Bronchial or Unknown Primary Neuroendocrine Tumors That Have Spread to the Liver NCT04544098 Memorial Sloan Kettering Cancer Center | Aktif, hasta almıyor | Erken faz 1 | 2 Eylül 2020 |
| Testing the Addition of an Anti-cancer Drug, Triapine, to the Usual Radiation-Based Treatment (Lutetium Lu 177 Dotatate) for Neuroendocrine Tumors NCT04234568 National Cancer Institute (NCI) Sonuç yayımlandı | Aktif, hasta almıyor | Faz 1 | 20 Temmuz 2020 |
| Lutathera for the Treatment of Inoperable, Progressive Meningioma After External Beam Radiation Therapy NCT04082520 Mayo Clinic | Hasta alıyor | Faz 2 | 14 Nisan 2020 |
| Dosimetry Based PRRT Versus Standard Dose PRRT With Lu-177-DOTATOC in NEN Patients NCT04917484 Tine Gregersen, MD | Hasta alıyor | Faz 2 | 1 Şubat 2020 |
| Study to Evaluate the Efficacy and Safety of Lutathera in Patients With Grade 2 and Grade 3 Advanced GEP-NET NCT03972488 Advanced Accelerator Applications Sonuç yayımlandı | Aktif, hasta almıyor | Faz 3 | 8 Ocak 2020 |
| PRRT Versus PRRT Plus Chemotherapy in GEP NET (PReCedeNT Trial) NCT07185672 Tata Memorial Hospital | Hasta alıyor | Faz 3 | 7 Ağustos 2019 |
| Phase II Study of 177Lu-DOTATATE Radionuclide in Adults With Progressive or High-risk Meningioma NCT03971461 NYU Langone Health | Aktif, hasta almıyor | Faz 2 | 15 Mayıs 2019 |
| Post-Authorization Long-Term Safety Study of LUTATHERA NCT03691064 Advanced Accelerator Applications | Aktif, hasta almıyor | — | 28 Kasım 2018 |